(Q43191501)

15 November 2017

title

CD133 expression predicts for non-response to chemotherapy in colorectal cancer (English)

1 reference

15 November 2017

1 reference

1 reference

6

1 reference

15 November 2017

Chee W Ong

1

1 reference

15 November 2017

Lay G Kim

2

1 reference

15 November 2017

Hui H Kong

3

1 reference

15 November 2017

Lai Y Low

4

1 reference

15 November 2017

Barry Iacopetta

5

1 reference

15 November 2017

Manuel Salto-Tellez

7

1 reference

15 November 2017

publication date

15 January 2010

1 reference

15 November 2017

1 reference

15 November 2017

volume

23

1 reference

15 November 2017

issue

3

1 reference

15 November 2017

page(s)

450-457

1 reference

Symmetric division of cancer stem cells--a key mechanism in tumor growth that should be targeted in future therapeutic approaches

15 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.181

7 January 2021

Cancer stem cells: models and concepts

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.181

7 January 2021

Stem cells, cancer, and cancer stem cells

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.181

7 January 2021

Human colon cancer stem cells: a new paradigm in gastrointestinal oncology

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.181

7 January 2021

Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.181

7 January 2021

A human colon cancer cell capable of initiating tumour growth in immunodeficient mice

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.181

7 January 2021

Identification and expansion of human colon-cancer-initiating cells

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.181

7 January 2021

CD133 expression is an independent prognostic marker for low survival in colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.181

7 January 2021

CD133 and nuclear beta-catenin: the marker combination to detect high risk cases of low stage colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.181

7 January 2021

CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.181

7 January 2021

Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.181

7 January 2021

CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.181

7 January 2021

Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.181

7 January 2021

Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.181

7 January 2021

Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.181

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.181

7 January 2021

TRARESA: a tissue microarray-based hospital system for biomarker validation and discovery.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.181

7 January 2021

Tissue microarrays characterise the clinical significance of a VEGF-A protein expression signature in gastrointestinal stromal tumours

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.181

7 January 2021

Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.181

7 January 2021

OCT4 immunohistochemistry is superior to placental alkaline phosphatase (PLAP) in the diagnosis of central nervous system germinoma.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.181

7 January 2021

Computer-assisted pathological immunohistochemistry scoring is more time-effective than conventional scoring, but provides no analytical advantage

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.181

7 January 2021

Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.181

7 January 2021

Stem cells in adult tissues

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.181

7 January 2021

Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.181

7 January 2021

Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.181

7 January 2021

Immunohistochemical detection of CD133 expression in colorectal cancer: a clinicopathological study.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.181

7 January 2021

Multimarker phenotype predicts adverse survival in patients with lymph node-negative colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.181

7 January 2021

Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.181

7 January 2021

CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.181

7 January 2021

Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.181

7 January 2021

Prospective identification of tumorigenic prostate cancer stem cells

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.181

7 January 2021

Identification of human brain tumour initiating cells

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.181

7 January 2021

Identification and expansion of the tumorigenic lung cancer stem cell population

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.181

7 January 2021

Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.181

7 January 2021

Highly infiltrative brain tumours show reduced chemosensitivity associated with a stem cell-like phenotype

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.181

7 January 2021

Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.181

7 January 2021

Reduced hGC-1 protein expression is associated with malignant progression of colon carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.181

7 January 2021

10.1038/MODPATHOL.2009.181

Identifiers

DOI

1 reference

Dimensions Publication ID

15 November 2017

1000994300

0 references

1 reference